Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy (Review)

Liu, Ting; Guo, Feng; Zhu, Xiaomin; He, Xu; Xie, Lin

doi:10.3892/etm.2017.5209

Cited by 16 publications

(13 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With an improved understanding of the mechanisms of action of thalidomide, it was found to have immunomodulatory, anti-inflammatory, antiangiogenesis and cell proliferation inhibitory properties suitable for treating various diseases. [295][296][297][298] Notably, thalidomide in combination with dexamethasone was approved by the FDA for treating multiple myeloma in 2006. 299 Further studies have indicated thalidomide has marked anticancer activity in various cancers by mediating angiogenesis.…”

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

364

315

View full text Add to dashboard Cite

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono-or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake.

show abstract

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

364

315

View full text Add to dashboard Cite

show abstract

“…(B) FDA approval of IMiDs (Aragon-Ching et al, 2007; FDA and CDER, 2014; Fala, 2015; Ríos-Tamayo et al, 2017). (C) Preclinical studies using IMiDs (Sampaio et al, 1991; Corral et al, 1996; Zhu et al, 2003; Baratz et al, 2015; Wang et al, 2016b; Decourt et al, 2017; Liu T. et al, 2017; Rubenstein et al, 2018).…”

Section: History and Mechanism Of Thalidomide (Figure 2)mentioning

confidence: 99%

Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments

Jung

Tweedie

Scerba

et al. 2019

Front. Cell Dev. Biol.

102

View full text Add to dashboard Cite

Neuroinflammation is initiated when glial cells, mainly microglia, are activated by threats to the neural environment, such as pathogen infiltration or neuronal injury. Although neuroinflammation serves to combat these threats and reinstate brain homeostasis, chronic inflammation can result in excessive cytokine production and cell death if the cause of inflammation remains. Overexpression of tumor necrosis factor-α (TNF-α), a proinflammatory cytokine with a central role in microglial activation, has been associated with neuronal excitotoxicity, synapse loss, and propagation of the inflammatory state. Thalidomide and its derivatives, termed immunomodulatory imide drugs (IMiDs), are a class of drugs that target the 3′-untranslated region (3′-UTR) of TNF-α mRNA, inhibiting TNF-α production. Due to their multi-potent effects, several IMiDs, including thalidomide, lenalidomide, and pomalidomide, have been repurposed as drug treatments for diseases such as multiple myeloma and psoriatic arthritis. Preclinical studies of currently marketed IMiDs, as well as novel IMiDs such as 3,6′-dithiothalidomide and adamantyl thalidomide derivatives, support the development of IMiDs as therapeutics for neurological disease. IMiDs have a competitive edge compared to similar anti-inflammatory drugs due to their blood-brain barrier permeability and high bioavailability, with the potential to alleviate symptoms of neurodegenerative disease and slow disease progression. In this review, we evaluate the role of neuroinflammation in neurodegenerative diseases, focusing specifically on the role of TNF-α in neuroinflammation, as well as appraise current research on the potential of IMiDs as treatments for neurological disorders.

show abstract

“…Thalidomide, an immunomodulatory, anti-fibrotic and anti-inflammatory drug, has previously been indicated by the US FDA for the treatment of erythema nodosum leprosum, systemic lupus erythematous, inflammatory bowel disease, cystic fibrosis, heart failure and several malignant anomalies ( 67 ). The anti-viral activity of thalidomide has been reported, leading to a surge in cellular immunity, i.e.…”

Section: Treatment Strategiesmentioning

confidence: 99%

Diagnostic and Treatment Strategies for COVID-19

et al. 2020

View full text Add to dashboard Cite

The world is facing lockdown for the first time in decades due to the novel coronavirus COVID-19 (SARS-CoV-2) pandemic. This has led to massive global economic disruption, placed additional strain on local and global public health resources and, above all, threatened human health. We conducted a review of peer-reviewed and unpublished data, written in English, reporting on the current COVID-19 pandemic. This data includes previously used strategies against infectious disease, recent clinical trials and FDA-approved diagnostic and treatment strategies. The literature was obtained through a systematic search using PubMed, Web of Sciences, and FDA, NIH and WHO websites. Of the 98 references included in the review, the majority focused on pathogen and host targeting, symptomatic treatment and convalescent plasma utilization. Other sources investigated vaccinations in the pipeline for the possible prevention of COVID-19 infection. The results demonstrate various conventional as well as potentially advanced in vitro diagnostic approaches (IVD) for the diagnosis of COVID-19. Mixed results have been observed so far when utilising these approaches for the treatment of COVID-19 infection. Some treatments have been found highly effective in specific regions of the world while others have not altered the disease process. The responsiveness of currently available options is not conclusive. The novelty of this disease, the rapidity of its global outbreak and the unavailability of vaccines have contributed to the global public's fear. It is concluded that the exploration of a range of diagnostic and treatment strategies for the management of COVID-19 is the need of the hour.

show abstract

Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy (Review)

Cited by 16 publications

References 80 publications

Overcoming cancer therapeutic bottleneck by drug repurposing

Overcoming cancer therapeutic bottleneck by drug repurposing

Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments

Diagnostic and Treatment Strategies for COVID-19

Contact Info

Product

Resources

About